INTRODUCTION
The recent advancements in high-throughput DNA sequencing have generated a series of complete genome sequences including those of mouse and man. The annotation of these genomes has resulted in a comprehensive directory of the genes that make up a living organism. After this initial phase of gene discovery, biomedical research is now faced with the challenge to elucidate the functions of individual genes in the context of the entire organism. Functional genome annotation will ultimately lead to comprehension of the genetic basis of human health and various disease conditions. The mouse is ideally suited for the functional analysis of the genome for several reasons: first, the mouse genome shows a high degree of homology with the human genome; second, the mouse has an excellent track record as a model system for human traits and diseases and finally, an arsenal of molecular and embryologic technologies makes it possible to easily mutate genes in mouse embryonic stem (ES) cells and to generate mice that carry defined mutations.
The European Conditional Mouse Mutagenesis Program (EUCOMM) takes the lead in saturation mutagenesis of the mouse genome, which will be the basis for functional annotation of the entire genome [1, 2] . This review describes the structure and the goals of the EUCOMM program as well as the technologies that have been implemented to generate this resource.
THE EUCOMM PROGRAM
EUCOMM is a collaborative effort of 9 participants from four European countries (Figure 1) Mutagenesis in EUCOMM will be performed in a high throughput manner using conditional gene trapping and conditional gene targeting strategies.
The conditional mutagenesis approach allows the analysis of gene functions in a time-and tissuespecific manner. This feature is especially important for about 20% of the genes whose non-conditional mutation causes embryonic lethality, thus precluding analysis at later stages [3, 4] . Furthermore, conditional mutagenesis will help to create better mouse models for those human disease conditions which are caused by somatic mutations in the adult patient. Thus, EUCOMM generates a unique resource that will, for the first time, permit to analyse gene function on a large scale.
The EUCOMM program will mutate a substantial fraction of the mouse genome. It is planned to produce up to 12 000 gene trap mutations and 8 000 gene targeting mutations in mouse ES cells. To facilitate the initial analysis of these mutations, EUCOMM will also generate up to 320 mutant mice from its resource. Furthermore, to increase the tools for conditional mutagenesis, EUCOMM intends to establish 20 ligand-inducible Cre driver lines with novel tissue-specific expression patterns. All EUCOMM reagents (plasmids, ES cells and mice) will form an open resource for the international scientific community.
Further details about the EUCOMM program can be found on the EUCOMM website www.eucomm.org. It should be noted that this webpage also provides access to the list of genes chosen for conditional gene targeting in EUCOMM, and scientists are invited to prioritize their genes of interest on this list (procedure described on EUCOMM website).
EUCOMM GENE TRAPPING
The gene trapping strategy relies on the random insertion of a gene trap vector into an intron of a transcribed gene [5] . The insertion of the vector disrupts the function of the trapped gene and simultaneously reports its expression. The main advantage of gene trapping is that a single vector can be used to mutate a large number of genes in a limited number of experiments. Gene trapping has been successfully applied to create a large collection of mutant mouse ES cells over the last 10 years (see the website of the International Gene Trap Consortium, www.genetrap.org [6] ). Based on previous gene trapping efforts, it is estimated that gene trapping can cover up to 60% of all mouse genes [7, 8] .
The EUCOMM gene trap vector is based on the FlipROSAbgeo vector, which is delivered to ES cells as a moloney murine leukemia virus (MMLV) retrovirus ( Figure 2A ). The promotorless trap cassette consists of a splice acceptor, a b-gal reporter, a neomycin resistance gene and a polyadenylation signal. To improve the trapping rates for genes encoding secreted or transmembrane proteins, a variant of the vector, rsFlipROSACeo, which contains an internal transmembrane domain, will be used in parallel [9] .
To achieve the conditionality of the trap alleles, the gene trap vector utilizes the FlEx technology developed by F. Schnütgen [10] . Two pairs of heterotypic recombination sites for the Cre and FLP recombinases, respectively, are positioned in inverted orientation around the trap cassette. This allows inverting the cassette two times. The first inversion silences the mutation and creates a conditional allele (Figure 2B-D) . The second inversion reinstates the mutation ( Figure 2E and F) .
The first inversion can be either done in vitro by transiently transfecting a trapped ES cell line with, for example, FLP recombinase, or in vivo by breeding a gene trap mouse line with a mouse line that expresses FLP in its germline ('FLP deleter mouse'). A mouse carrying such an inverted, i.e. conditional, allele can then be bred to Cre driver lines. Depending on the expression properties of the respective Cre line, the mutation can be selectively reactivated in a time-and tissue-specific manner. Alternatively, Cre recombinase can be introduced into a defined tissue location by viral delivery.
Gene trapping is a random mutagenesis approach; consequently, the rate of newly trapped genes will decline continuously during the course of trapping [3] . When the trapping rate of new genes is no longer cost efficient, the EUCOMM gene trapping efforts will switch completely to gene targeting.
EUCOMM GENE TARGETING
Gene targeting, also known as 'Knock-out', relies on homologous recombination to introduce a DNA vector into a chosen locus [11] . The EUCOMM targeting vectors will be mainly designed as promoterless targeting vectors that contain a splice acceptor ('targeted trapping'; [12] ). The promoterless design makes such vectors more selective for correct recombination events, thus increasing the targeting frequencies and reducing the effort necessary for obtaining targeted ES cell clones.
Similar to gene trapping, the 'targeted trapping' strategy can only hit genes that are expressed in ES cells. Because of that, the first set of EUCOMM target genes is assembled from genes that are present at least once in a public or private gene trap resource (indicating that these genes are amenable to promoterless targeting). Genes that are not expressed in ES cells will be targeted with a vector that contains a neomycin resistance gene driven by a phosphoglycerine kinase (PGK) promoter.
The conditional gene targeting vectors are generated from a bacterial artificial chromosome (BAC) library of mouse genomic DNA by recombineering technology [13] . The EUCOMM targeting vector was developed by W. Skarnes and B. Rosen at the Sanger Institute based on a strategy described by F. Stewart and colleagues [14] . The vector contains a targeting cassette with a splice acceptor followed by a b-gal reporter and a neomycin resistance gene that disrupt gene function and report gene expression in a similar manner to the gene trap vector. The targeting cassette is flanked by FRT sites, so that it can be removed by FLP recombinase. In addition, the vector contains two loxP sites that flank a critical exon ( Figure 3A) . The deletion of this critical exon by Cre recombinase causes a frame shift between the remaining exons, and thus the complete disruption of gene function.
To convert a targeted allele into a conditional allele, the targeting cassette has to be removed first by FLP recombination (Figure 3C ). In a mouse that carries such a conditional allele, gene activity can then be selectively inactivated by Cre recombinase, which can be introduced either as transgene or by viral delivery (Figure 3D ). If a conditional allele is not desired, it is also possible to use Cre recombinase directly on the original allele to create a lacZ-tagged null allele ( Figure 3E ).
EUCOMM CRE LINES
To complement the library of conditional alleles, the EUCOMM program will also generate up to 20 new mouse lines that will express ligand-inducible Cre recombinase in a tissue-specific manner. Amongst these lines will be mice that express Cre, for example, in certain subsets of muscle or heart cells, subsets of pancreatic cells or subsets of neurons such as adult neuronal stem cells, serotonergic or dopaminergic neurons. These lines will be made either by pronuclear injections of BACs that contain particular promoter regions of genes together with a cassette encoding Cre, or by recombinase-mediated cassette exchange in EUCOMM ES cells (replacing the trapping/targeting cassette with a Cre cassette). The version of Cre enzyme that will be used for EUCOMM will be one that is inducible by tamoxifen (Cre-ER T2 ), which enables temporal control of Cre activation [15] .
THE EUCOMM RESOURCE
The EUCOMM ES cell lines will be distributed centrally by the EUCOMM Distribution Center at the GSF Research Center in Munich-Neuherberg. Access to the database of EUCOMM genes can be found under www.eucomm.org. The EUCOMM Distribution Center will also send out the intermediate and final plasmid vectors used for EUCOMM gene targeting. It is noteworthy that these plasmids can be easily modified by users to generate knock-outs of their own design.
The mice generated in the EUCOMM project will be archived as frozen embryos or sperm for long-term storage. The European Mouse Mutant Archive network (EMMA; www.emmanet.org) will disseminate the mutant mice to the scientific community upon request.
THE INTERNATIONAL MOUSE KNOCKOUT CONSORTIUM
To make the functional annotation of the entire mouse genome achievable over the next few years, it had been recognized by leading biomedical scientists that it is essential to coordinate the different international mouse mutagenesis programs [1, 2] . The cornerstones of this worldwide mutagenesis effort are the European EUCOMM program, the US 'KnockOut Mouse Project' (KOMP) and the Canadian 'North American Conditional Mouse Mutagenesis Project' (NorCOMM), which together form the International Mouse Knockout Consortium (IMKC; [16] ). To this international initiative, EUCOMM plans to contribute the largest fraction of mutant mouse ES cell lines. Furthermore, EUCOMM put forward the use of conditional mutagenesis, an approach which has been adopted by most IMKC partners. It is planned to exchange the EUCOMM, KOMP and NorCOMM resources to establish a unique, comprehensive resource useful for scientists worldwide.
